Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement Attractive financial outlook Compelling sustainability story
Growth driven by launches in the US and strong
performance in Europe and International
Net sales by region
2023 2028 (illustrative)
=
Mid-single digit growth¹
2023
Europe
North America
International
2028
1. In constant currencies. For additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31.
•
23
Management Presentation
Europe consistently
performing above the market
• ~25% growth contribution
Leverage footprint with
new launches
North America with US
returning to growth
• ~50% growth contribution
•
Growth primarily driven by four
high-value Biosimilars launches
Leveraging growth in
International markets
~25% growth contribution
Prioritize first-to-market
and Biosimilars launches
SANDOZView entire presentation